Clinical trial
Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant…
NCT04857840 · Quantum Genomics SA, Industry · Terminated
Key facts
| NCT number | NCT04857840 |
|---|---|
| Title | Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH) |
| Official title | A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients With Difficult-to-treat/Resistant Hypertension. |
| Acronym | REFRESH |
| Lead sponsor | Quantum Genomics SA, Industry |
| Collaborators | PRA Health Sciences Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension (HTN) |
| Intervention type | Drug |
| Interventions | Firibastat (QGC001) Period 1 |
| Enrollment | 419 |
| Start date | Aug 5, 2021 |
| Primary completion | Jan 9, 2023 |
| Completion | Jan 9, 2023 |
| First posted | Apr 23, 2021 |
| Last update posted | Jan 17, 2023 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: